BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

NextEdge Admin

15 Nov 2024

2 min 47 sec

Exact Sciences Corp. , a leader in cancer screening and diagnostics, will present advancements in multi-cancer early detection (MCED) at the American Association for Cancer Research (AACR) Special Conference on Liquid Biopsy from November 13-16, 2024. Recent studies demonstrate how Exact Sciences’ new multi-biomarker approach enhances sensitivity for early-stage cancer detection. Modeling data suggest that adding MCED testing to current screening protocols may lower stage IV cancer incidence and reduce cancer mortality over a 10-year period. Another analysis from the DETECT-A study indicates that MCED testing could complement current lung cancer screening without impacting adherence to standard care.

Tom Beer, M.D., Exact Sciences’ chief medical officer, emphasized the urgency of advancing early detection, noting that only 14% of cancers in the U.S. are diagnosed through screening, despite cancer's trajectory to become the leading cause of death by 2030. “We believe MCED testing is our single biggest opportunity to combat these stark statistics,” Beer said. He highlighted Exact Sciences’ dedication to developing rigorous, evidence-backed multi-cancer screening solutions.

New research shows that a multi-biomarker MCED test, which incorporates a DNA mutation reflex in addition to DNA methylation and protein (MP) markers, increases sensitivity by 28% for stage I cancers and 12.5% for early-stage cancers in a case-control study, excluding breast and prostate cancer and with 98.5% specificity. This multi-biomarker approach demonstrates significant potential for detecting more cancers earlier.

Exact Sciences’ MCED product, known as Cancerguard™, remains in development and has not been FDA-approved. Built on a streamlined imaging-based diagnostic pathway, Cancerguard is designed to minimize false positives and reduce follow-ups. This effort aligns with Exact Sciences’ ongoing commitment to innovative cancer solutions, which began with the success of Cologuard® and Oncotype® tests.